Crawford cleared of affair allegations

Share this article:
An internal investigation has found no basis for the anonymous charges that Acting FDA commissioner Lester Crawford had an extramarital affair with an agency employee or acted inappropriately because of such a relationship, the Associated Press reported this afternoon.
The inquiry by the inspector general of the Department of Health and Human Services did however cite inconsistencies in the manner in which the woman was promoted and assistance that Crawford may have given her, the AP report said. The identity of the woman has not been disclosed.
Sen. Mike Enzi, a Wyoming Republican, told Reuters he had "full confidence" in Crawford's ability to lead the FDA and would move forward as soon as possible with Crawford's nomination to serve as permanent FDA commissioner.
However, it remains unclear if the nomination would get the full vote of the Senate.
Democratic senators, Hillary Rodham Clinton of New York and Patty Murray of Washington, have promised to place a hold on the nomination and have criticized the FDA for not allowing over-the-counter sales of the Barr Laboratories' Plan-B contraceptive.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...